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Abstract: The hypothesis for this study is that weaning to an extensively
hydrolyzed infant formula will decrease the incidence of type 1 diabetes
(T1D), as it does in all relevant animal models for the disease. This will be
tested in children who carry risk-associated human leukocyte antigen
genotypes and have a first-degree relative with T1D. The trial will use
a double-blind, prospective, placebo-controlled intervention protocol,
comparing casein hydrolysate with a conventional cow’s milk (CM)-based
formula. A secondary aim is to determine relationships between CM
antibodies, a measure of CM exposure, and diabetes-associated auto-
antibodies. To achieve an 80% power for the detection of a 40%
intervention-induced difference in the development of autoantibodies and
subsequent diabetes, the study requires 2032 subjects. A multicenter,
international, collaborative effort is necessary to achieve recruitment
targets. A collaborative international study group of 78 clinical centers in
15 countries has therefore been assembled for this purpose.
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Substantial progress has been made in understanding
autoimmune diabetes. However, the principal mech-
anisms that initiate and mediate the process of b-cell
destruction remain obscure. Large collaborative ef-
forts over the last 15 yr have consolidated our view of
the diabetes-prone host. Thus, nearly 90% of subjects
will carry one of a small number of disease-associated
human leukocyte antigen (HLA) genotypes, protective
alleles are rare, and autoantibodies to different islet
cell proteins accumulate progressively as strong
harbingers of impending disease. The Trial to Reduce
IDDM in the Genetically at Risk (TRIGR) has its
roots in both human epidemiological and rodent
experimental studies. Although hypothetical causes of
diabetic autoimmunity remain controversial, the best
strategy for disease prevention in diabetes-prone BB
rats and non-obese diabetic (NOD) mice uses hypo-
antigenic weaning diets, based on amino acids or
extensively hydrolyzed casein (1–12). The ultimate
goal of animal studies is the translation of their results
to the human disease. The major secondary type 1
diabetes (T1D) prevention trials are good examples
(13–15), and TRIGR is the first primary prevention
effort.
Genetic risk factors
The role played by genetics in T1D is illustrated by
family and genetic marker studies. Compared to the
general population, first-degree relatives of patients
with T1D have a markedly increased risk of T1D,
which varies with the risk within the background
population of the region (16). Siblings of a patient may
have a 6–8% average rate of diabetes development by
adulthood, but this rate can reach 12–19% if the sibling
and patient share the same high-risk HLA haplotypes
(17). If they are identical twins, approximately 20–30%
of the siblings will develop diabetes (18, 19), this rate
increasing in the presence of a high-risk genotype (20).
Children of affected mothers have a 1.5–2.5% diabetes
risk; the rate in children of affected fathers is 3–6% (21–
23). The most important genetic risk markers for T1D
are located within the HLA class II region. The protein
products encoded by class II genes are expressed on
antigen-presenting cells. They capture and present
processed peptide antigen to the T-cell receptor –
a central event in the initiation of any immune
response. HLA-DQ heterodimer molecules encoded
by DQA1 and DQB1 genes are most strongly
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associated with disease susceptibility (24). The highest
risk is associated with the genotype containing two
different susceptibility genotypes (DR4-DQ8/DR3-
DQ2), whereas the risk associated with a double dose
of individual haplotypes is not markedly higher than
the single dose without protective markers. This
synergism between risk haplotypes may reflect the
creation of new heterodimer molecules encoded by A1
and B1 genes in trans position.
HLA-DR4 subtypes among DR4-DQ8 haplotypes
confer different risks, and DRB1*0403 and *0406
alleles seem to be dominantly protective (25). Approx-
imately 80% of Caucasian subjects with T1D have at
least one of the HLA susceptibility haplotypes, but
these are also present in about 30% of the general
population. This suggests interactions with one or
more of the other genes that have been identified, with
broad similarities between human and syngenic
regions in NOD mouse genomes (26, 27). About 20
risk loci have been mapped in humans, but only the
insulin gene region on chromosome 11 and to a lesser
extent CTL4 have been consistently established to
affect risk in man but play a lesser role than HLA in
the predisposition to diabetes (28, 29).
Environmental risk factors
A low twin concordance of 20–30% (30, 31) rapid
shifts in incidence (32), as well as large variations in
diabetes incidence in humans (33) and among different
colonies of inbred, diabetes-prone rodents (34), all
contribute to the evidence that progression of diabetic
autoimmunity is driven by interactions of environ-
mental factors with the products of predisposing and
protective genes (35, 36). Risk-associated environmen-
tal factors remain largely unproved, but some infec-
tious and nutritional agents, and toxins have been
proposed (32, 37). Enteroviral infection, in particular
Coxsackie B4, attracted renewed interest (38–43), and
in diabetes-prone NOD mice, this virus can accelerate
(but not initiate) prediabetes progression (44). There
clearly are b-cell selective toxins (45–46), while the
partial IL-12 antagonist, vitamin D3, has diabetes-
protective effects at least in rodents (47). However,
a universal relevance of these elements to autoimmune
diabetes in the population at large is uncertain.
Complex diets as a prerequisite for
rodent diabetes
Diabetes-prone BB rats and NOD mice are models for
the human disease, and while differences exist, the list
of similarities is long and detailed (48–51).
Following the early observation that amino acid-
based weaning diets protected BB rats from overt
diabetes (1), numerous studies analyzed dietary
disease prevention in rodents (reviewed by Scott
et al. (11)]. Although diverse in design, focus and
conclusions, there is one common thread in these
studies: complex weaning diets, such as the multicom-
ponent standard rodent chows, are actually a pre-
requisite for high-incidence diabetes development (2).
In contrast, hypoantigenic protein sources, such as
amino acids or extensively hydrolyzed casein, prevent
the development of diabetes (11). Although there can
no longer be dissention that weaning diets affect
diabetes development, mechanisms remain uncertain
and controversial (52).
Spurred by the observation that early weaning to
cow’s milk (CM)-based formula is a diabetes risk factor
in humans (reviewed in ref. 32, 37) and by abnormal
immunity of NOD mice to CM protein (53) attempts to
identify specific proteins in CM as initiators of islet
autoimmunity found considerable (54), intermediate
(55), or little diabetogenicity (8, 52). However, none of
these studies were able to mimic the human situation of
early weaning to exclusively CM proteins, and high
oral doses of the whey protein, bovine serum albumin
(BSA), actually showed some protection (52).
Collectively, there is one consensus conclusion
common to all these studies (5, 9, 12, 52): a very clear
protection from diabetes is afforded by weaning to
extensively hydrolyzed casein formulas, while a par-
tially hydrolyzed protein diet rich in potentially anti-
genic peptides retains diabetogenicity (7).
Despite considerable differences in study design, not
a single published experiment failed to result in disease
protection with hydrolyzed casein as weaning diet
in high- or low-incidence, BB rat or NOD mouse
colonies. This became the basis and intervention
strategy for TRIGR.
Does the weaning diet affect human diabetes?
There are many indications that the pathogenetic
process leading to manifest T1D may start very early
in life in some cases, even in utero (56, 57). In addition,
during childhood the incidence of the disease has
shifted toward younger age in several countries over
the last decades (58), providing added impetus for
studies of environmental factors, including complex
weaning diets in the first years of life.
The first evidence in man for an association between
weaning diet and the risk of T1D comes from a case–
control study showing an inverse correlation between
the duration of breastfeeding (BF) and diabetes risk
(59). Numerous subsequent studies explored this re-
lationship with various study designs, power, and focus
on candidate offenders such as CM protein, often
the sole protein source, in particular for very young
weanlings. With two exceptions, all retrospective stud-
ies used general population controls genetically
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resistant to diabetes, and few distinguished between
exclusive BF and formula-supplemented feeding
periods (60, 61). The study by Virtanen et al. showed
that age at introduction of CM was inversely related
to risk of diabetes independently of both exclusive and
total BF (60). Meta-analyses confirmed the positive
conclusions of the majority of studies with an overall
significant but small risk attributed to early formula
exposure (62, 63). However, conclusions have re-
mained controversial (64), and the complexity of
issues surrounding diet and T1D was compounded
by large studies that attributed elevated diabetes risk
to high liquid CM exposure later in the life of
previously exposed children (65–67), a factor that
may obscure pure weaning effects. The risk of T1D
described in two case-control studies indicates that
there might be an interaction between increased
genetic disease susceptibility, based upon HLA class
II allels, and an early introduction of supplementary
milk feeding during infancy (68, 69). Disease risk
may also be affected by the interaction between
genetic susceptibility and a large intake of CM later
in life (67).
Data from a prospective study of 1610 German
children (70) concluded that there might be an
association of T1D risk and early cereal exposure,
but no association of CM exposure and T1D risk. The
nature and extent of CM exposures were not reported,
but 50% of infants in Germany are weaned to
hydrolyzed formula. A cohort study from Denver (71)
analyzed 1183 children (0.7–7 yr old) with increased
genetic susceptibility to T1D. They found no associ-
ation between early CM exposure and b-cell autoanti-
bodies. In this study, 259 children had early cereal
exposure (before the age of 4 months) and 13 deve-
loped autoantibodies, whereas 105 had late exposure
(at the age of 7 months or later) and 7 seroconverted
to autoantibody positivity. In contrast to the German
study, a significant association was observed for both
early (odds ratio 3.03) and late exposure (odds ratio
3.86). The numbers of infants with early exposure to
gluten (n ¼ 85 with four seroconverters) were too
small to draw any conclusions regarding gluten as
a risk factor for b-cell autoimmunity. Early CM
exposure (,3 months) showed a non-significant pro-
tection from autoimmune seroconversion. The likeli-
hood of confounding is increased by using exposures
at 4–6 months as the reference group since this time
period was the recommended age for introduction of
cereals. These studies and their partly discordant
conclusions are difficult to evaluate because of a lack
of statistical power and because the main autoanti-
bodies detected (.80%) were insulin autoantibodies
(IAA).
In a third prospective study from Australia, life-
table analysis failed to detect an association between
CM exposure and autoantibodies. Intriguingly, oppo-
site conclusions can be drawn of very significant risk
associations caused by short BF and early CM
exposure, which are apparent from data tabulated in
the same paper (72). These data show that formula
was introduced at a mean age of 3.5 months in
children who developed at least two autoantibodies,
compared to 7 months in autoantibody-negative
children (p , 0.0001).
In the prospective population-based Finnish Type 1
Diabetes Prediction and Prevention Study (73),
newborn infants from the general population were
tissue typed and those with risk HLA genotypes were
recruited for a nested, prospective case–control study.
The first 65 children who seroconverted to islet cell
antibodies (ICA) positively before the age of 4 yr
(cases) were compared with 390 ICA-negative control
subjects, matched for date of birth, gender, and HLA-
DQB1 genotype. The risk of IA-2 autoantibody
positivity or positivity for all four autoantibodies
measured (ICA, insulin, GAD and IA-2 autoanti-
bodies) was lower in children exclusively breastfed for
more than 4 months compared to those who were
breastfed for 2 months or less [odds ratio 0.24, 95%
confidence interval (CI) 0.06–0.94, for IA-2A positiv-
ity; odds ratio 0.17, 95% CI 0.03–0.86, for positivity
for four antibodies]. Infants weaned to standard CM
formula before the age of 4 months were at increased
risk of IA-2A positivity (odds ratio 4.37, 95% CI 1.33–
14.4, for ,2 months vs. 4 months; odds ratio 5.50,
95% CI 1.21–25.0, for 2–3.9 months vs. 4 months) or
positivity for all four autoantibodies (odds ratio 5.02,
95% CI 1.27–19.9, for ,2 months vs. 4 months;
odds ratio 6.19, 95% CI 1.10–34.7, for 2–3.9 months
vs. 4 months). The associations remained significant
after adjustment for maternal age, duration of
maternal education and 12-month relative weight
and height of the child. These observations suggest
that short BF and early introduction of CM-based
infant formula predispose young children at increased
genetic risk for diabetes to the development of
progressive b-cell autoimmunity.
These results were the impetus for a double-blind,
randomized pilot trial of weaning either to a casein
hydrolysate (Nutramigen, Mead Johnson Nutrition-
als, Evansville, IL, USA) or to a conventional CM-
based formula until the age of 6–8 months in 242
infants (74). The results indicated a substantial reduc-
tion in the cumulative incidence of b-cell autoimmunity
with continued follow-up to the age of 5–7 yr. After
adjustment for duration of study formula feeding, life-
table analysis showed protection by the intervention
from the development of ICA (p ¼ 0.02) and one or
more autoantibodies (p ¼ 0.03). A similar trend was
seen in the development of overt T1D (currently three
vs. nine of those exposed to the study formula). Thus,
despite its limited power, the pilot study provides the
first evidence ever in man that it may be possible to
TRIGR study design
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deviate spontaneous b-cell autoimmunity by dietary
intervention in infancy. The current international
TRIGR is powered to provide a definitive test of the
hypothesis that weaning to a hydrolyzed formula
protects against initiation and progression of T1D.
Study design (Fig. 1)
Recruitment
Extensive recruiting strategies focus on the identifica-
tion of newborn infants with a first-degree relative
who has T1D. In addition to major television, news-
paper, magazine, and website publicities, mothers
with T1D are identified during pregnancy via endo-
crinologists or high-risk pregnancy services. Fathers
with T1D are identified by (i) available history or data
already in the medical record of pregnant women; (ii)
interviewing women at prenatal maternity clinic visits;
and (iii) existing registries of T1D in some centers.
Pregnant women with one or more children affected
by diabetes are identified through various pediatric
diabetes clinics. Consent is obtained primarily during
pregnancy and rarely, in some countries, at delivery.
Potentially eligible subjects meet protocol inclusion
and exclusion criteria (Table 1) insofar as possible
prior to the baby’s delivery and are reassessed after
birth.
Intervention
BF is encouraged. Babies are randomized to receive
either a regular CM-based infant formula or an
extensively hydrolyzed CM formula upon weaning
from breast milk in the first 6–8 months of life. Other
formulas and cow protein products are avoided.
Study formula
Each study formula is a nutritionally complete infant
formula (Nutramigen powder), manufactured by one
company (Mead-Johnson Nutritionals), containing
extensively hydrolyzed casein as the protein source,
vegetable oils as the fat source, and glucose polymers
and modified starch as the carbohydrate source. The
control formula is a mixture of commercial routine
CM-based formula powder made by the same com-
pany (Enfamil) plus casein hydrolysate powder in
a 4:1 ratio in order to mask the flavor and smell
differences between the two study formulas. This casein
hydrolysate has been shown to be non-diabetogenic in
the BB rat (52) and NOD mouse models (12).
The formulas are packed in four different colors –
two colors for test formula and two colors for control
formula. The four-color coding scheme is well tested
in infant formula studies, is found to aid the blinding
process, and provides a hard control for randomiza-
tion during data analysis, while avoiding accidental
miss-shipments as the families recognize their’ color.
Subjects are allocated to receive one-color formula
box, which is maintained throughout the study.
Randomization’ of the babies to one of the four-
color coded test formulas stratified by geographic
region is implemented after 35 wk of gestation or
immediately after birth prior to the availability of HLA
eligibility results. Randomization is assigned by the
Data Management Unit (DMU) via the TRIGR
website with the system available 24 h/d to the research
assistant or investigator. This early randomization
allows immediate use of study formula whenever BF
is not available. Any subject requiring supplemental
feeding in the nursery prior to randomization (e.g.,
unrandomized infants born at night or on weekends) is
given either banked breast milk or casein hydrolysate.
Eligibility’ is determined by HLA-typing blood
obtained from cord blood at birth whenever possible
or alternatively by a heel prick performed within 7 d
after birth. The blood sample and/or blood spot on
filter paper is forwarded to the continental genotyping
center, and screening is performed for the presence of
the increased risk HLA genotypes listed below.
Results are sent via the DMU to the central project
office and the investigator within 5–7 d. Only subjects
with the risk HLA genotypes (approximately 45%) are
included in the nutritional prevention trial.
Implementation of intervention
All recruited mothers are encouraged to breastfeed.
The planned duration of the intervention is until at
least 6 months of age with the goal of a minimum of
2 months daily exposure to the study formula. If the
mother chooses to exclusively breastfeed up to the age
of 6 months, she will be asked, thereafter, to give the
Experimental Group
n=1016
Control Group
n=1016
At risk genotypes
n=2032
Exclude low risk genotypes
n=2904
Genotyping on cord  blood
Randomization at 35 weeks Gestation
Mothers consent to Screening
(approx 85%)
n=4516
Encourage breast feeding. Study
formula until the child is 6 months
of age or if the child is exclusively
breast fed for 5 or 6 months then
study formula for 2 months.
Encourage breast feeding. Study
formula until the child is 6 months
of age or if the child is exclusively
breast fed for 5 or 6 months then
study formula for 2 months.
Fig. 1. TRIGR study design.
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study formula for at least 2 months, i.e., until the age
of 8 months. Similarly, if exclusive BF lasts for 5
months, the infant would receive study formula until
the age of 7 months. Infant BF practices are altered as
little as possible by the trial and is entirely at the
discretion of participating mothers. The rationale for
the 6–8 month intervention period is based on the
following considerations: in early infancy, the child
receives the major part of energy in liquid form, either
as human milk or as CM-based formula. The period
chosen provides a reasonable and practical safety
margin over the 2- to 3-month vulnerable’ time when
the gut is permeable to proteins, as suggested in
several epidemiological studies (reviewed in 32).
Dietary advice is provided by a dietitian member of
the study team, before or soon after delivery; at the
2-wk telephone call to notify the HLA-typing result;
at the 1-, 2-, 4-, and 5-month telephone calls; and at
the 3- and 6-month visits. If the infant continues in the
intervention after the age of 6 months, the family is
called also at 7 and 8 months of age. The families
receive both written and oral instructions about infant
feeding during the intervention period including
pamphlets, which describes the sequence and amounts
of food recommended at specific ages, according to
local guidelines. The use of soy-based infant formula
is not encouraged because it could replace the study
formula. Parents are provided with a list of all solid
foods, giving choices of brand names that can be given
to the infant and that do not contain CM protein; they
are also provided with a list of foods not recom-
mended which do contain CM protein. Dietary advice
leaflets, field book, dietary forms, and questionnaires
were translated into 11 relevant languages and
adapted to national practices before the start of
enrollment. Postintervention diets follow generally
accepted practices. After randomization, Nutramigen
is used in case of suspected or proved study formula
intolerance.
Study assessments (Fig. 2)
Baseline
At the time of randomization, medical and perinatal
history of the infant and mother (including birth-
weight and gestational age) and the results of the
newborn physical examination are recorded on the
case report forms.
Follow-up during and after intervention
The subjects have blood draws at the research center,
or a satellite or home visit at the ages of 3, 6, 9, 12, 18,
and 24 months and then annually until 10 yr of age or
when clinical T1D develops. The presence or absence
of diabetes is determined according to the criteria
outlined (see Outcome Assessment). Clinical findings
at each visit (e.g., weight, height) are recorded on the
case report forms.
Blood samples for measurements of the b-cell auto-
antibodies are drawn (after the application of an
analgesic cream at the venipuncture site) at each visit.
In addition, the 3- and 6-month serum samples are
used for measurements of CM antibodies for the
assessment of dietary compliance. All serum samples
Table 1. TRIGR inclusion and exclusion criteria
Newborn infants who have first-degree relatives with T1D (i.e., a mother, father, or sibling) and who meet the inclusion
but not the exclusion criteria will be recruited:
Inclusion criteria
(i) The biological parent and/or full (not half) sibling of the newborn infant has T1D as defined by the
World Health Organization.
(ii) The infant’s parents or legal guardians give signed consent to participate.
(iii) The infant has one of the following genotypes:
(a) HLA-DQB1*0302/DQA1*05-DQB1*02;
(b) HLA-DQB1*0302/x (x not DQB1*02, DQB1*0301, or DQB1*0602);
(c) HLA-DQA1*05-DQB1*02/y (y not DQA1*0201-DQB1*02, DQB1*0301, DQB1*0602, or DQB1*0603);
(d) HLA-DQA1*03-DQB1*02/y (y not DQA1*0201-DQB1*02, DQB1*0301, DQB1*0602, or DQB1*0603).
Exclusion criteria
(i) An older sibling of the newborn infant has been included in the TRIGR intervention.
(ii) Multiple gestation.
(iii) The parents are unwilling or unable to feed the infant CM-based products for any reason
(e.g., religious, cultural)
(iv) The newborn infant has a recognizable severe illness such as those caused by chromosomal
abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc.
(v) The gestational age of the newborn infant is less than 35 wk.
(vi) Inability of the family to take part in the study (e.g., the family has no access to any of the study centers,
the family has no telephone).
(vii) The infant has received any infant formula other than Nutramigen prior to randomization.
(viii) The infant is older than 7 d at randomization (applicable to subjects randomized after birth).
(ix) No HLA sample drawn before the age of 8 d.
TRIGR study design
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are aliquoted and stored centrally at 270C. Meas-
urement of plasma glucose and glycated hemoglobin
is performed locally at 12, 18, and 24 months and then
annually until 10 yr. The specimens for plasma
glucose are preferentially drawn 1–2 h postprandially.
If the glycated hemoglobin is higher than the normal
range, an additional oral glucose tolerance test
(OGTT) may be required to confirm the diagnosis.
Oral glucose tolerance tests are performed in all
subjects at 6 and 10 yr of age.
Monitoring of compliance and
retention strategy
The diet of the child and the compliance with the
avoidance of intact CM proteins are assessed at the
delivery hospital by interview; by a telephone interview
when the child is 2 wk and 1, 2, 4, and 5 months old; and
at 3- and 6-month visits. If the infant continues in the
intervention after the age of 6 months, telephone
interviews are done also at 7 and 8 months of age.
Dietary interviews record by means of a structured form
information on the duration of total and exclusive BF,
the age at introduction, duration of study formula
feeding, and amount of study formula given per feeding.
In addition, the families are asked about the frequency
of BF and the frequency of use of study formula, several
allowed foods (potato and vegetables, fruit and berries,
cereals, meat, fish, dietary supplementation), and non-
recommended foods and food groups (infant formulas
other than the study formula, foods containing CM or
beef protein). In addition, at the 2-wk interview, the
feeding during the first 3 d is enquired: all types of
milk feeding given and the most frequently used milk
feeding. Study formula distribution form is completed
always when formula is given to the family (amount
and code of formula). Unused formula must be
returned to the local study center at each appropriate
clinical visit (6 and possibly 9 months) in order to get
an estimate of total formula exposure. Compliance
with the avoidance of intact CM proteins is also
assessed by measuring CM protein antibody levels
from sera at 3 and 6 months, and the results correlated
with the information received by dietary forms.
Outcome assessment
The major outcome for the first phase will be the
frequency of T1D associated autoantibodies and/or
the development of clinical diabetes by the age of 6 yr.
The outcome of the second phase will be the mani-
festation of diabetes by the age of 10 yr. The manifest
diabetes outcome is assessed as the proportion of
subjects in each group who develop T1D, as well as
the age at diagnosis. These subjects will be classified as
having T1D if they fulfill one of the following criteria:
(i) on daily insulin injections and at least one of the
following:
(a) a history of ketoacidosis;
Fig. 2. Procedures at the time of birth and at each follow-up call and visit.
The TRIGR Study Group
122 Pediatric Diabetes 2007: 8: 117–137
(b) at least two fasting plasma glucose levels 7.0
mmol/L;
(c) a random plasma glucose 11.1 mmol/L plus (b)
or symptoms;
(d) two random plasma glucose levels.11.1 mmol/L;
(ii) a fasting plasma glucose 7.0 mmol/L and/or
a plasma glucose of 11.1 mmol/L at 2 h after
ingestion of 1.75 g of glucose/kg (to a maximum of
75 g) body weight [i.e., a diabetic oral glucose tolerance
test according to the ADA/WHO criteria (75)]. A
diabetic oral glucose tolerance has to be confirmed by
a second test.
Laboratory methods
Genetic screening
The procedures used for HLA-DQ typing were
specifically developed for screening relevant DQB1
and DQA1 alleles (76, 77). Ethylenediaminetetraacetic
acid-treated cord blood is collected and a blood spot
prepared on filter papers. Alternatively, capillary
blood is taken directly on the filter paper. The filter
papers are sent from the US and Canadian centers to
the tissue-typing laboratory of Dr M. Trucco,
University of Pittsburgh, PA, USA, and from the
various European and other centers to the tissue-
typing laboratory of Dr J. Ilonen, University of
Turku, Finland. The results are electronically commu-
nicated to the DMU and, by them, sent by e-mail to
the central project office and the hospital in question.
Autoantibodies
ICA, IAA, antibodies to the 65-kDa isoform of
glutamic acid decarboxylase (GADA), and antibodies
to the protein tyrosine phosphatase-related IA-2
molecule (IA-2A) are humoral markers of b-cell auto-
immunity. All autoantibody analyses will be performed
in the laboratory of Dr M. Knip (University of Helsinki).
ICA are analyzed with a standard immunofluores-
cence assay performed on sections of frozen human
pancreas from a blood group O donor (78). Fluores-
cein-conjugated anti-human IgG (Sigma, St Louis,
MO, USA) is used to detect ICA. All initially ICA-
positive samples are retested to confirm antibody
positivity. End-point dilution titers are identified, and
the results are expressed in Juvenile Diabetes Foun-
dation (JDF) units relative to an international
reference standard (79). The detection limit is 2.5
JDF units. The sensitivity of this ICA assay was 100%,
the specificity 98%, the validity 98%, and the consis-
tency 98% in the most relevant international standard-
ization round (80).
IAA are measured with a microassay, modified
from that described by Williams et al. (81). The cut-off
limit for IAA positivity [2.80 relative units (RU)] is
based on the 99th percentile in 344 non-diabetic
children. Samples with an initial IAA titer between the
97th and 99.5th percentiles are reanalyzed to verify the
antibody status. The disease sensitivity of the IAA
microassay was 44% and its specificity 98% in the
CDC-sponsored Diabetes Autoantibody Standardiza-
tion Program (DASP) Workshop in 2002.
GADA are detected in an immunoprecipitation
radioligand assay (82). The cut-off limit for anti-
body positivity is set at the 99th percentile in 373
non-diabetic children and adolescents, i.e., 5.36 RU
(corresponding to 20.90 WHO units/mL). All sam-
ples with an initial GADA level between the 97.5th
and 99.5th percentiles are reanalyzed to verify the
antibody status. This assay had a sensitivity of
82% and a specificity of 98% in the 2002 DASP
Workshop.
IA-2A are detected in a similar radiobinding assay
(83). A subject is considered IA-2A positive, if the
serum antibody levels are equal to or exceed 0.77 RU
(corresponding to 16.46 WHO units/mL), which
represents the 99th percentile in 374 non-diabetic
Finnish children and adolescents. Samples with an
initial IA-2A level between the 97.5th and 99.5th
percentiles are reanalyzed to verify the antibody
status. The disease sensitivity of this assay was 66%
and the specificity 100% in the 2002 DASP Workshop.
Antibodies to CM Proteins
CM antibodies (IgG, IgA, and IgM), b-lactoglobulin
antibodies (IgG and IgA) (84), b-casein antibodies
(IgG and IgA), and BSA antibodies (IgG and IgA)
(85) are measured with modifications of the original
enzyme-linked immunosorbent assay techniques by
Dr E. Savilahti, Helsinki, Finland.
Biostatistical considerations
Randomization
This is a randomized double-blinded intervention
study using an intention-to-treat statistical analysis
to compare the incidence of predictive autoantibodies
and clinical T1D in the two treatment groups.
Recruitment is carried out during a 4-yr period in 6
major centers in the USA, in 18 centers in Canada, in
51 centers in 12 Europen countries, and 3 centers in
New South Wales, Australia. To facilitate recruitment
and to minimize any possibility of unintentional
exposure to CM protein, every attempt is made to
identify and randomize eligible families before the
child is born. Written consent is obtained at this time;
the child participates after birth if he/she meets the
inclusion but not exclusion criteria. Families not
TRIGR study design
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identified until just prior to the onset of maternal
labor may be approached at that time.
The children are randomly assigned to the two
treatment groups in a 1:1 ratio using randomly per-
muted blocks. Randomization is balanced within each
participating center/country.
Sample size and power
The sample size estimate is based on experiences from
family studies analyzing the occurrence of autoanti-
bodies in siblings of children with T1D or in offspring
of affected parents and progression to clinical disease
in such young first-degree relatives. The data on the
frequency of multiple (2) autoantibodies by the age
of 6 yr and the cumulative incidence of T1D by the
age of 10 yr are based on 82 young siblings from
the DiMe Study carrying increased genetic risk for
T1D (86).
Nineteen out of 325 offspring (5.9%) with increased
genetic risk according to the criteria used in the Pilot-2
trial tested positive for at least one autoantibody by
the age of 2.4 yr in the German BABYDIAB study
(87). Seventeen of these 19 subjects (89%) developed
multiple autoantibodies during prospective observa-
tion. Assuming a constant increase in autoantibody
frequency from ages 2 to 6 yr, the expected cumulative
incidence of at least one antibody would be 14.8% and
that of at least two antibodies 13.0% by the age of
6 yr, which is well within the 95% CI of the observed
frequency of 20.7% of multiple autoantibodies in the
young DiMe siblings.
The cumulative incidence of at least one autoanti-
body by the age of 4 yr was 10.6% in siblings and
offspring of affected subjects in the DAISY study
from Denver (88). Published data are not available,
allowing an estimation of the frequency of at least one
or two autoantibodies in subjects with increased
genetic risk as defined in the Pilot-2 trial. Neverthe-
less, a constant increase in the frequency of at least
one autoantibody from ages 4 to 6 yr would result in
an autoantibody prevalence of 15.9% by the age of
6 yr in siblings and offspring irrespective of HLA-
defined genetic risk. The data from the DiMe study
were used for the power calculation as it includes the
largest long-term follow-up of young relatives.
The projected sample size of 2032 infants to be
randomized for the trial is based on the following
assumptions:
(i) a confidence level of 95%;
(ii) a statistical power of 80%;
(iii) a reduction of 40% in the hazard rate of T1D in
the intervention group;
(iv) a dropout rate of 20%;
(v) a frequency of 10% of exclusive BF up to the age
of 6 months
These figures represent a conservative estimate
because they are based on the lower 95% CI (7.6%)
of the observed cumulative incidence of T1D by the
age of 10 yr (15.4%) in young siblings with moderate
(DQB1*0302/x) and slightly increased genetic risk
(DQB1*02/y). In the Pilot-2 trial, the prevalence of the
high-risk genotype (DQB1*02/0302) was about two
times higher (absolute frequency 20%) among siblings
of affected children than among offspring of affected
parents.
To achieve that number, 4516 infants must be
screened assuming a frequency of 45% of the genotypes
conferring increased risk (see Fig. 1). The observed
prevalence of risk genotypes was 46% among the 474
infants screened for the Pilot-2 trial.
Infants are to be recruited over a 4-yr period and
the planned follow-up will be 6 yr after the last infant
has been accrued for the antibody end-point and
10 yr after the last infant is accrued for the T1D end-
point. Thus, all subjects will have at least 10 yr of
follow-up.
Analysis plan
Two hypotheses will be tested. The first hypothesis is
that the children in the group fed casein hydrolysate
will have a decreased occurrence of diabetes-associ-
ated antibodies in comparison with the control group
receiving conventional CM-based formula. The sec-
ond hypothesis is that the group weaned to a casein
hydrolysate formula has a reduced incidence of T1D.
The Kaplan–Meier method will be used to construct
survival curves and the log-rank statistic to compare
treatment arms with respect to time until the devel-
opment of autoimmunity or type 1 diabetes mellitus
(T1DM). Secondary analyses will be carried out using
the proportional hazards regression model (89),
including milk exposure as a risk factor and potential
confounding factors as time-dependent covariates in
the model. Baseline variables that will be used in
stratified analyses include gender, HLA risk category,
and other prognostic characteristics. If differences in
baseline characteristics are observed, analyses will be
conducted of the effects of the treatments on out-
comes adjusting for the potential confounding effects
of these baseline characteristics. If only a few differ-
ences in such baseline characteristics are identified,
analyses will be conducted stratifying for these
characteristics. If any more than a few baseline
characteristics are identified because of small sample
size, it will be necessary to use regression models to
adjust the treatment comparison for the confounding
effects of these characteristics.
A number of subgroup analyses are planned to help
identify individuals more likely to benefit from, or to be
harmed by, the treatment. Such subgroups might include
gender, gender of the relative with T1DM, HLA risk
The TRIGR Study Group
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group, and other factors suspected to be associated with
the event. Exploratory data derived through subgroup
analyses will serve primarily to generate new hypotheses
for subsequent testing, and conclusions drawn from
subgroup hypotheses not explicitly stated before data
analysis will have less credibility than those from hypo-
theses stated in the protocol.
Interim analysis
A Data and Safety Monitoring Board (DSMB) has
been created by National Institutes of Health to
monitor this trial. In addition to semiannual reviews
of accrual and safety, the DSMB has planned two
interim analyses to assess whether large treatment
differences have emerged early or there is insufficient
reason to expect that differences will occur. The
analysis will use the approach to group sequential
testing that has been presented by Lan and DeMets
(90) for which neither the number of looks nor the
increments between looks must be prespecified.
Rather, Lan and DeMets only require specification
of the rate at which the type I error, e.g., total alpha ¼
0.05, will be ’spent’. This procedure allows ’spending’
a little of alpha at each interim analyses in such a way
that, at the end of the study, the total type I error does
not exceed, e.g., 0.05. An alpha or spending function
is defined in terms of time. One alpha function
generates boundaries that are nearly identical to the
O’Brien-Fleming boundaries. Time can be thought of
either as information time (the fraction of information
available at any point in the study) or as calendar time
(the portion of the study time already passed) (91).
For ease of implementation, exposure time will be
used (92). The fraction of exposure time will in general
approximate the true fraction of information and,
regardless of the underlying hazard functions, will
provide a group sequential procedure with the desired
alpha level. The boundaries will be two-sided (5%),
symmetric O’Brien-Fleming-type boundaries as imple-
mented by Lan and DeMets to minimize the likeli-
hood of confronting a large critical value prematurely.
The Lan–DeMets procedure will be formally applied
to the primary analysis, which is most important in
terms of leading to a decision to stop the trial pre-
maturely because of significant differences.
Organization and administration
The trial is executed by a multinational consortium of
clinical research groups. The international central
coordinating center with the study principal investi-
gator is located in Helsinki (Dr H.K. A˚kerblom and
his deputy, Dr M. Knip). The three major regional
groups are (i) Europe and Australia, with a coordi-
nating center in Helsinki; (ii) Canada with a coordi-
nating center in London, ON, Canada (Dr J. Dupre´);
and (iii) the USA, with a coordinating center in
Pittsburgh, PA (Dr D. Becker).
The essential laboratory functions required for
TRIGR are conducted in three central internationally
recognized study laboratories for determination of (i)
diabetes-related autoantibodies (Dr M. Knip, Hel-
sinki); (ii) compliance through measurements of CM
antibodies (Dr E. Savilahti, Helsinki); and (iii) MHC
typing for Europe (Dr J. Illonen, Turku) and for
North America (Dr M. Trucco, Pittsburgh).
The study coordinating center is located in Tampa,
FL (Dr J. Krischer). In the Helsinki center, Dr S.M.
Virtanen is responsible for the follow-up and report-
ing of dietary compliance for the whole TRIGR based
on data from Tampa center. Each region operates
through its Executive Committee, which is a sub-
committee of the Regional Steering Committee
representing all clinical centers.
Significance
The data reviewed in the background section empha-
size that diabetic autoimmunity in rodents has at least
one early prerequisite for its development: exposure to
complex diets. Thus, in inbred animals, living in con-
ditions sheltered from many environmental influences
and invariably breastfed, weaning diet is a critical
initiator or, in the case of casein hydrolysate, pre-
venter of progressive autoimmunity. Epidemiological
data accumulated in humans are more difficult to
interpret, but the results of our pilot studies emphasize
the similarities. Weaning to casein hydrolysate affects
the development of diabetic autoimmunity, in rodents
and, apparently, in man. This strategy is the first to
have such an impact in man. The TRIGR consortium
reached a consensus that the TRIGR is feasible, pro-
mising, and necessary.
The consequences costs of T1D presenting in
childhood are immense, not only economically and
for the society but also with regard to human life.
Microvascular complications develop in a considerable
proportion of the patients affecting their quality of
life. Those individuals manifesting T1D in childhood
and adolescence may have a severalfold increased risk
of macrovascular complications in adult life. It is
therefore obvious that major benefits would result if
we could prevent T1D even in a proportion of cases.
The TRIGR constitutes the first ever primary pre-
vention trial for T1D. In contrast to secondary preven-
tion strategies that attempt to arrest the progression
of established islet autoimmunity detected through
screening, the innocuous TRIGR strategy could be
applied to the general population with increased
genetic risk from where some 90% of the new cases
of T1D are derived.
Screening for TRIGR began on 1 May 2002, and
the target enrollment was achieved by 1 September
TRIGR study design
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2006. Through November 2006, the study has met or
exceeded all of its planning parameters in terms of
expected duration of exclusive BF (,4% at 6 months
of age) and subject retention and follow-up (.95% at
3 yr). Interim results are regularly presented to
a DSMB and formal analyses follow the plan outlined
above. According to the study timetable, the 6-yr
autoantibody results will be available in 2012 and the
T1D results in 2016.
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